Cargando…
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
There has been greater interest in developing additional antimicrobial agents due to the increasing health care costs and resistance resulting from bacterial pathogens to currently available treatment options. Gram-negative organisms including Enterobacteriaceae and Pseudomonas aeruginosa are some o...
Autores principales: | Hidalgo, Jose A, Vinluan, Celeste M, Antony, Nishaal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970634/ https://www.ncbi.nlm.nih.gov/pubmed/27528799 http://dx.doi.org/10.2147/DDDT.S110946 |
Ejemplares similares
-
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016) -
Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
por: Tan, Che-Kim, et al.
Publicado: (2019) -
In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018
por: Lemos-Luengas, Elkin V., et al.
Publicado: (2022) -
Ceftazidime/avibactam for specified infections
Publicado: (2020) -
Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam
por: Bassetti, Matteo, et al.
Publicado: (2020)